ZYNERBA PHARMACEUTICALS, INC.
CIK 0001621443
Revenue (TTM)
$86K
Q2 Aug 2023
Net Income (TTM)
−$39.42M
+6.1% YoY
Q2 Aug 2023
EPS Diluted (TTM)
−$0.86
+13.7% YoY
Q2 Aug 2023
Gross Margin
—
Q2 Aug 2023
Operating Margin
-45,661.7%
Q2 Aug 2023
Net Margin
-45,836.1%
Q2 Aug 2023
Free Cash Flow (TTM)
−$27.27M
Q2 Aug 2023
Cash
$35.97M
Q2 Aug 2023
Total Debt
—
Q2 Aug 2023
Shares Outstanding
53.94M sh
Q2 Aug 2023
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.